Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

.m. on 1 August 2012, (or such later date as agreed by the Company).

Convertible Loan Note

The Company also announces today the conditional issue of a £1 million Convertible Loan Note to Robert Keith.  The principal terms of the Convertible Loan Note are:

  • repayment on 1 August 2019, seven years after issue, if not previously converted into Ordinary Shares;
  • convertible into newly issued Ordinary Shares at the Issue Price;
  • convertible at any time from issue to maturity.

The price at which the Convertible Loan Note will convert into Ordinary Shares is subject to adjustment in certain circumstances.  The Convertible Loan Note is secured by way of a pledge by the Company over the entire issued share capital of Silence AG and by a pledge by Silence AG of certain intellectual property rights owned by Silence AG.

In addition to the Convertible Loan Note, the Company has conditionally granted warrants over 7,500,000 Ordinary Shares, to ISM Capital pursuant to the CL Warrant.  The warrants will be exercisable at a price of 1 pence at any time prior to the expiry of 36 months from the date of the CL Warrant.

The Convertible Loan Note and the CL Warrant are conditional, inter alia, upon the passing of Resolutions 1 to 3 and 8 and 9 (as set out in the Notice of General Meeting), the Share Capital Reorganisation occurring  and Admission of the New Ordinary Shares.

Establishment of an Equity Finance Facility

The EFF provides Silence with a £10 million facility which (subject to certain limited restrictions) can be drawn down at any time over the next three years. The timing and value of any draw down is at the sole discretion of the Company.

Silence is under no obligation to make a draw down.  The Company may make draw downs up to the total value of the EFF by way of issuing subscription notices to
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Senior supply chain management executives ... addressed the challenges of “Reducing Cost, Lead Time, & ... strategic sourcing. Describing the partnership of the Bio Supply ... Management Institute ( SCMI) of the University of ... at the Kroc Institute of Peace and Justice in ...
(Date:7/10/2014)... 2014  Kainos Capital, a firm specializing in acquiring ... it has acquired the Slim-Fast brand from Unilever. Unilever ... of the transaction were not disclosed. Slim-Fast ... that markets ready-to-drink shakes, powders, bars and snacks to ... and in the United Kingdom ...
(Date:7/10/2014)... July 10, 2014   Ceres, Inc . (Nasdaq: ... company, announced today financial results for the three months ... its business. Ceres reported that the company ... performance this growing season in Brazil, which concluded in ... company,s sorghum evaluation areas for part of the growing ...
(Date:7/10/2014)... 17, 2014 Using microscopic polymer light resonators ... researchers at MIT,s Quantum Photonics Laboratory have developed ... the parts-per-billion range. Optical sensors are ideal for ... signal-to-noise ratio, compact, lightweight nature, and immunity to ... had been developed before, the MIT team conceived ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Kainos Capital Acquires Slim-Fast From Unilever 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Swell new sensors 2
... , FLORHAM PARK, N.J., June 1 Today, BASF filed ... District of Delaware against DuPont (E. l. du Pont de ... confers tolerance to a key class of herbicides. Specifically, DuPont,s ... an important genetic component that enables successful tolerance toward an ...
... NOVATO, Calif., June 1 Raptor Pharmaceuticals Corp. ... today announced that it has dosed the first ... in collaboration with the University of California, ... delayed-release cysteamine bitartrate ("DR Cysteamine") capsules in nephropathic ...
... - Results Presented at American Society of Clinical Oncology ... with Favorable Pharmacokinetics and Prolonged Stable Disease in Refractory ... Mersana Therapeutics presented preliminary results of a Phase ... in a poster session at the 2009 Annual Meeting ...
Cached Biology Technology:BASF Sues DuPont for Patent Infringement 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 3Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 4Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 5Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors 2Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors 3
(Date:7/10/2014)... in New Mexico, nearly every public golf course is ... potable water supplies. Across the U.S. Southwest as a ... treated effluent. Reusing the effluent increases the sustainability of ... alike fertilize their lawns during the growing season. The ... State University turfgrass expert has a new vision for ...
(Date:7/10/2014)... YORK , June 27, 2014  Pomerantz ... Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) ... filed in United States District Court, Middle District ... is on behalf of a class consisting of ... acquired Provectus securities between December 17, 2013 and ...
(Date:7/10/2014)... SPRINGS, Florida , July 1, 2014 ... wallets pave way for convenience and improved security: NXT-ID, Inc. ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... and MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) ... is pleased to announce that the second series of 30 ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5
... 22, 2011 - The Vilcek Foundation is pleased to announce ... of foreign-born scientists and artists. The sixth annual ... sustained record of innovation and achievement, is awarded to Dutch-born ... of the laboratory of Cell Biology and Genetics at Rockefeller ...
... (BRONX, NY) Ertuğrul zbudak, Ph.D. , assistant ... of Medicine of Yeshiva University, has won a ... his research into the genetic causes of vertebral malformations that ... adult diseases, including scoliosis, disfigurement, and back and neck pain. ...
... 2011) -- A lab at Rice University has stepped forward ... that preserves their unique properties -- and adds more. ... functionalities to remain in close contact with single-walled carbon nanotubes ... separation is critical to manufacturers who want to spin fiber ...
Cached Biology News:Vilcek Foundation names recipients of 2011 Vilcek Prizes in Biomedical Science 2Vilcek Foundation names recipients of 2011 Vilcek Prizes in Biomedical Science 3Albert Einstein College of Medicine geneticist wins Sloan Research Fellowship 2Metallic molecules to nanotubes: Spread out! 2Metallic molecules to nanotubes: Spread out! 3
UBN-1 (C-20)...
P2A4...
pETDuet-1 is designed for the coexpression of two target genes....
... Cl- Cotransporter-1 (KCC1). The ... sequence homology with other ... The immunogen sequence is ... mouse, porcine and rabbit. ...
Biology Products: